📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Oculis Holding AG (OCS)

NASDAQ
Currency in USD
Disclaimer
11.729
+0.004(+0.03%)
Closed
OCS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
11.36011.800
52 wk Range
9.05014.500
Prev. Close
11.725
Open
11.7
Day's Range
11.36-11.8
52 wk Range
9.05-14.5
Volume
13,866
Average Vol. (3m)
30,811
1-Year Change
-5.14%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
OCS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
26.031
Upside
+121.937%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Oculis Holding AG Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.